ArticleInfectious diseases and therapy2024
Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019.
Article in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- The risk of cardiac disease events after respiratory syncytial virus disease: a systematic literature review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Estimating the respiratory syncytial virus-associated hospitalisation burden in older adults in European countries: a systematic analysis.BMC medicine · 2025Pooled it
- Trial
- Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the Netherlands.Infectious diseases and therapy · 2026Article
- Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Country-Level RSV-Related Hospitalisation Rates Among Adults in High-Income Countries From an Ensemble Model Based on Direct Viral Testing Incidence Data.Influenza and other respiratory viruses · 2026Article
- Incidence of RSV- and Influenza-Associated Hospitalizations With Community-Acquired Pneumonia and Other Acute Respiratory Infection Among Adults in Japan in 2022-2024: APSG-J2 Study.Influenza and other respiratory viruses · 2026Article
- Article
- Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus-Related Hospitalization.JAMA network open · 2026Article
- Estimated Incidence of All-Cause Respiratory Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Finland between 2011 and 2019: A Retrospective Database Study.Journal of epidemiology and global health · 2026Article
- Article
- Article
- Estimation of General Practitioner Visits, Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus and Influenza Virus, and Costs Associated With Hospitalizations, in Older Adults in France From 2010 to 2020.Open forum infectious diseases · 2025Article
- RSV Monitoring in Germany: A Critical Overview of Available Surveillance Systems.Journal of clinical medicine · 2025Review
- Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Norway between 2010 and 2019: A Time-Series Modelling Study.Journal of epidemiology and global health · 2025Article
- Detection by Nasopharyngeal Swabs Alone Underestimates Respiratory Syncytial Virus-Related Hospitalization Incidence in Adults: The Multispecimen Study's Final Analysis.The Journal of infectious diseases · 2025Article
- Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: application of the Global Burden of Disease framework.EClinicalMedicine · 2025Article
- In-Hospital Mortality and Severe Respiratory and Renal Outcomes-A Territory-Wide Comparison Between RSV and Influenza.Influenza and other respiratory viruses · 2025Article
- Estimated Incidence Rate of Specific Types of Cardiovascular and Respiratory Hospitalizations Attributable to Respiratory Syncytial Virus Among Adults in Germany Between 2015 and 2019.Influenza and other respiratory viruses · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRespiratory syncytial virus (RSV) burden in adults is underestimated mainly due to unspecific symptoms and limited standard-of-care testing. We estimated the population-based incidence of hospitalization and mortality attributable to RSV among adults with and without risk factors in Germany.
methodsWeekly counts of hospitalizations and deaths for respiratory, cardiovascular, and cardiorespiratory diseases were obtained (Statutory Health Insurance database, 2015-2019). A quasi-Poisson regression model was fitted to estimate the number of hospitalizations and deaths attributable to RSV as a function of periodic and aperiodic time trends, and viral activity while allowing for potential overdispersion. Weekly counts of RSV and influenza hospitalizations in children < 2 years and adults ≥ 60 years, respectively, were used as viral activity indicators. Models were stratified by age group and risk status (defined as presence of selected comorbidities).
resultsPopulation-based RSV-attributable hospitalization incidence rates were high among adults ≥ 60 years: respiratory hospitalizations (236-363 per 100,000 person-years) and cardiorespiratory hospitalizations (584-912 per 100,000 person-years). RSV accounted for 2-3% of all cardiorespiratory hospitalizations in this age group. The increase in cardiorespiratory hospitalization risk associated with underlying risk factors was greater in 18-44 year old persons (five to sixfold higher) than in ≥ 75 year old persons (two to threefold higher).
conclusionsThis is a first model-based study to comprehensively assess adult RSV burden in Germany. Estimated cardiorespiratory RSV hospitalization rates increased with age and were substantially higher in people with risk factors compared to those without risk factors. Our study indicates that RSV, like other respiratory viruses, contributes to both respiratory and cardiovascular hospitalizations. Effective prevention strategies are needed, especially among older adults ≥ 60 years and among adults with underlying risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.